Liquid Biopsy Market Report 2026

The liquid biopsy market size has grown rapidly in recent years. It will grow from $1.46 billion in 2025 to $1.71 billion in 2026 at a compound annual growth rate (CAGR) of 17.3%. The growth in the historic period can be attributed to limitations of traditional tissue biopsy procedures, increasing global cancer incidence, early adoption of blood-based diagnostics, advancements in molecular biology techniques, growing focus on early cancer diagnosis.

The liquid biopsy market size is expected to see rapid growth in the next few years. It will grow to $3.11 billion in 2030 at a compound annual growth rate (CAGR) of 16.2%. The growth in the forecast period can be attributed to rising demand for precision oncology, increasing adoption in routine cancer screening, expanding applications in recurrence monitoring, growth in oncology diagnostic spending, increasing awareness among clinicians and patients. Major trends in the forecast period include rising adoption of non-invasive cancer diagnostics, increasing use of liquid biopsy for early cancer detection, growing demand for real-time treatment monitoring, expansion of liquid biopsy in personalized oncology, rising clinical acceptance as an alternative to tissue biopsy.

The rise in government funding for the advancement of cancer detection is a major driver of growth in the liquid biopsy market. Such funding is largely due to the increasing global burden of cancer, the necessity for early diagnosis to enhance treatment outcomes, and the emphasis on lowering healthcare costs through innovative diagnostic technologies. Government support aids liquid biopsy by accelerating research and development, backing clinical trials, and encouraging the adoption of advanced, non-invasive diagnostic methods to improve early cancer detection and personalized treatment approaches. For example, in October 2024, gov.UK, a UK-based government website, reported that a total of £118 ($150.38 million) was allocated to UK Research and Innovation, with £54 million from the government and £64 ($81.55 million) million from partners. Therefore, the increase in government funding for the advancement of cancer detection is fueling the growth of the liquid biopsy market.

Major companies in the liquid biopsy market are concentrating on developing innovative solutions, such as comprehensive circulating tumor DNA (ctDNA) genomic-profiling assays, to accelerate noninvasive cancer profiling, enable faster therapeutic decisions, and expand access to precision oncology when tissue samples are limited or unobtainable. A ctDNA comprehensive genomic-profiling assay examines fragments of tumor-derived cell-free DNA circulating in the blood to detect somatic small variants, copy-number changes, insertions/deletions, and immuno-oncology signatures (e.g., bTMB and bMSI), providing broader tumor insights without the invasiveness, sampling bias, and longer turnaround times associated with traditional tissue biopsies. For example, in November 2023, Illumina Inc., a US-based sequencing and genomics company, introduced TruSight Oncology 500 ctDNA v2, a research-use liquid biopsy panel for noninvasive genomic profiling of solid tumors, combining an expanded hybrid-capture panel with DRAGEN bioinformatics to sequence 523 biomarkers from low cfDNA input. The assay enriches and detects SVs, CNVs, indels, and immuno-oncology metrics with high analytical performance, offers streamlined workflows through a single hybridization step and a < 4-day turnaround, and is compatible with NovaSeq systems and upcoming automation. It can be used when tissue is unavailable or delayed, complements tissue testing, and supports broad pan-cancer research and trial screening, providing faster insights, suitability for low-input samples, and easier adoption across distributed laboratory environments.

In February 2024, Veracyte Inc., a US-based diagnostics company, acquired C2i Genomics Inc. for $70 million. Through this acquisition, Veracyte plans to enhance its diagnostics platform by incorporating whole-genome minimal residual disease (MRD) capabilities. The acquisition enables Veracyte to leverage C2i's AI-driven technology for more accurate detection of circulating tumor DNA from blood samples, aiming to broaden its cancer care offerings. C2i Genomics Inc. is a US-based company providing AI-powered liquid biopsy solutions for cancer diagnostics.

Major companies operating in the liquid biopsy market are QIAGEN NV, Roche Diagnostics Ltd., Bio-Rad Laboratories Inc., Myriad Genetics Inc., Guardant Health Inc., Thermo Fisher Scientific Inc., Biocept Inc., Trovagene Inc., Fraunhofer-Gesellschaft, MDX Health SA, Agilent Technologies Inc., Illumina Inc., Oxford Nanopore Technologies Ltd., Quantum Biosystems Inc., Menarini Silicon Biosystems Inc., Pathway Genomics Corporation, Sysmex Corporation, Janssen Global Services LLC, Natera Inc., ANGLE Plc, Bio Techne Corp, Biodesix Inc., CellMax Inc., CIRCULOGENE, Exact Sciences Corporation, Epic Sciences Inc., Exosome Diagnostics Inc., GRAIL Inc., Inivata Ltd., NIPD Genetics, Oncocyte Corporation, Personal Genome Diagnostics Inc., RainDance Technologies Inc., Thrive Earlier Detection Corp.

North America was the largest region in the liquid biopsy market in 2025. Western Europe was the second largest region in the liquid biopsy market. The regions covered in the liquid biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the liquid biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the liquid biopsy market by increasing costs associated with imported assay kits, advanced diagnostic instruments, and sequencing technologies. These effects are more pronounced across ngs instruments and assay kit segments, particularly in regions such as asia-pacific and europe that rely on cross-border diagnostic technology supply chains. Reference laboratories and hospitals face higher testing and operational costs due to tariff-related pricing pressures. On the positive side, tariffs have encouraged local manufacturing of diagnostic kits, regional laboratory expansion, and supply chain diversification, supporting long-term market resilience.

The liquid biopsy market research report is one of a series of new reports that provides liquid biopsy market statistics, including liquid biopsy industry global market size, regional shares, competitors with a liquid biopsy market share, detailed liquid biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the liquid biopsy industry. This liquid biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A liquid biopsy is a fast and painless alternative to surgical biopsies that enables medical professionals to gather extensive information about a tumor from a small blood sample. It is a diagnostic test conducted on blood to identify the presence of cancerous cells and is used for detecting cancer at an early stage.

The main product types of liquid biopsy include assay kits, instruments, and services. Assay kits supply the reagents necessary to perform analytical tests for measuring specific analyses in industries such as food, cereals and dietary fiber, dairy, analytical laboratories, animal feed and nutrition, biofuels, biotechnology, wine, malting and brewing, and research. The various clinical applications include early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring, which are utilized by reference laboratories, hospitals and physician laboratories, as well as academic and research centers.

The liquid biopsy market includes revenues earned by entities by DNA collection tubes, tests, and reagents. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.